The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Pursuing the leadlikeness concept in pharmaceutical research
Abstract
Lipinski and others, through concepts such as drug-likeness, re-focussed drug discovery back to the principles of medicinal chemistry in the high-throughput era as key to reducing attrition. More recently, the need to go further in defining what makes a good lead has been recognised with the concept of leadlikeness. Leadlikeness implies cut-off values in the physico-chemical profile of chemical libraries such that they have reduced complexity (e.g. MW below <400) and other more restricted properties. We examine these concepts in the context of Virtual (theoretically possible), Tangible (chemically feasible) and Real (physically available) worlds of molecules. In a thought experiment, we take the HTS concept to the extreme: screening an estimated 60 million 'Global Collection' on 5000 targets and realising that perhaps millions of drug candidates might be found that could not possibly be handled in reality. Sampling of the Virtual and Tangible worlds is therefore a necessity. We show that the world of Reals is significantly under-sampled as the MW of compounds increases. This supports the design and screening of 'reduced complexity' (leadlike) compound libraries, preferably with synthetic handles available for rapid chemical iteration and detected as interesting by careful screening or biophysical assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Encyclopedia of Computational Chemistry
(1998) · Wiley eBooks · doi:10.1002/0470845015 · Cited by 2,742
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
Self-citationThe Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
Self-citationThe maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Cited by
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
“A strong emphasis on the physicochemical properties of compounds — using concepts such as drug-like properties and lead-like properties”
BackgroundCombining docking and molecular dynamic simulations in drug design
Alonso, H., Bliznyuk, A. A., & Gready, J. E. (2006) · Medicinal Research Reviews · doi:10.1002/med.20067 · Cited by 759
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200700139 · Cited by 709
Virtual Screening Strategies in Drug Discovery: A Critical Review
Lavecchia, A., & Giovanni, C. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990001 · Cited by 686
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach
Kapetanovic, I. M. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.006 · Cited by 662
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
Dobson, P. D., & Kell, D. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2438 · Cited by 475
Exploring biology with small organic molecules
Stockwell, B. R. (2004) · Nature · doi:10.1038/nature03196 · Cited by 470
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208749 · Cited by 466
Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
Szymański, P., Markowicz, M., & Mikiciuk-Olasik, E. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms13010427 · Cited by 454
Development and validation of a modular, extensible docking program: DOCK 5
Moustakas, D. T., Lang, P. T., Pegg, S., Pettersen, E., Kuntz, I. D., Brooijmans, N., & Rizzo, R. C. (2006) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-006-9060-4 · Cited by 440
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Self-citationLead‐Oriented Synthesis: A New Opportunity for Synthetic Chemistry
Nadin, A., Hattotuwagama, C., & Churcher, I. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201105840 · Cited by 390
The 7 TM G‐Protein‐Coupled Receptor Target Family
Jacoby, E., Bouhelal, R., Gerspacher, M., & Seuwen, K. (2006) · ChemMedChem · doi:10.1002/cmdc.200600134 · Cited by 359
A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library
Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., & Austin, C. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061317y · Cited by 358
The p KaDistribution of Drugs: Application to Drug Discovery
Manallack, D. T. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100003 · Cited by 354
Rayan, A., Raiyn, J., & Falah, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187925 · Cited by 351
Chemical predictive modelling to improve compound quality
Cumming, J. G., Davis, A. M., Muresan, S., Haeberlein, M., & Chen, H. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4128 · Cited by 311
Going further than Lipinski's rule in drug design
Walters, W. P. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.648612 · Cited by 306
Interpreting steep dose-response curves in early inhibitor discovery.
Shoichet, B. K. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061103g · Cited by 304
Novel Chemical Space Exploration via Natural Products
Rosén, J., Gottfries, J., Muresan, S., Backlund, A., & Oprea, T. I. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801514w · Cited by 280
Self-citationAssessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276
Self-citationDereplication: racing to speed up the natural products discovery process
Gaudêncio, S. P., & Pereira, F. (2015) · Natural Product Reports · doi:10.1039/c4np00134f · Cited by 264
Peña, I., Pilar Manzano, M., Cantizani, J., Kessler, A., Alonso-Padilla, J., Bardera, A. I., Alvarez, E., Colmenarejo, G., Cotillo, I., Roquero, I., et al. (2015) · Scientific Reports · doi:10.1038/srep08771 · Cited by 260
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
Kawakami, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.009 · Cited by 259
Hit discovery and hit-to-lead approaches
Keserű, G. M., & Makara, G. M. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.016 · Cited by 256
Modeling the expansion of virtual screening libraries
Lyu, J., Irwin, J. J., & Shoichet, B. K. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01234-w · Cited by 193
Fragment Informatics and Computational Fragment‐Based Drug Design: An Overview and Update
Sheng, C., & Zhang, W. (2013) · Medicinal Research Reviews · doi:10.1002/med.21255 · Cited by 80
Continuous‐Flow Solid‐Phase Peptide Synthesis: A Revolutionary Reduction of the Amino Acid Excess
Mándity, I. M., Olasz, B., Ötvös, S. B., & Fülöp, F. (2014) · ChemSusChem · doi:10.1002/cssc.201402436 · Cited by 65
Protein‐protein interactions as antibiotic targets: A medicinal chemistry perspective
Cossar, P. J., Lewis, P. J., & McCluskey, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21519 · Cited by 55
Neumann, L., Ritscher, A., Müller, G., & Hafenbradl, D. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9288-x · Cited by 20
Early ADME/T Predictions: Toy or Tool?
Tetko, I. V., & Oprea, T. I. (2008) · Chemoinformatics Approaches to Virtual Screening · doi:10.1039/9781847558879-00240 · Cited by 5
Self-citation
Metadata
- Authors
- Hann, M. M., & Oprea, T. I.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 8
- Issue
- 3
- Pages
- 255-263
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2151028167
- Cited by
- 515
- References
- 42
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.